e-learning
resources
London 2016
Tuesday, 06.09.2016
Do we really need PD1/PD-L1 status and next generation sequencing to treat lung cancer?
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Is Next Generation Sequencing Resting (NGSR) ready for clinical practice? Pro
Joanna Chorostowska-Wynimko (Warszawa, Poland)
Source:
International Congress 2016 – Do we really need PD1/PD-L1 status and next generation sequencing to treat lung cancer?
Session:
Do we really need PD1/PD-L1 status and next generation sequencing to treat lung cancer?
Session type:
Lunchtime session
Number:
4466
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Joanna Chorostowska-Wynimko (Warszawa, Poland). Is Next Generation Sequencing Resting (NGSR) ready for clinical practice? Pro. International Congress 2016 – Do we really need PD1/PD-L1 status and next generation sequencing to treat lung cancer?
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ICU admission of lung cancer patients – Is COVID-19 a game-changer?
Surgical vs non-surgical treatment of early stage non-small cell lung cancer: here's the fight
N3 hilar sampling decision in the staging of mediastinal lung cancer
Related content which might interest you:
Is PD1/PD-L1 Resting ready for clinical practice? Pro
Source: International Congress 2016 – Do we really need PD1/PD-L1 status and next generation sequencing to treat lung cancer?
Year: 2016
Blood biomarkers: ready for practice?
Source: ERS Research Seminar 2018 – Lung Cancer Screening: from Trial to Practice
Year: 2018
Spirometry longitudinal data analysis software (SPIROLA) in a routine clinical laboratory
Source: International Congress 2014 – Respiratory function: quality and new technologies
Year: 2014
Line Probe Assay as a preliminary investigation for diagnosing resistant tuberculosis : A Single center experience
Source: Virtual Congress 2020 – Multidrug-resistant tuberculosis
Year: 2020
Workstation 1: Approach to full polysomnography, setting up and wiring up: the basic techniques
Source: International Congress 2015 – EW25 Hands-on polysomnography
Year: 2015
Genomics and system biology: where does it take us in the future?
Source: Annual Congress 2011 - PG3 Workshop: Genomics and proteomics of lung disease
Year: 2011
Workstation 2: Data acquisition: what can go wrong? What does it look like when it goes right?
Source: International Congress 2015 – EW25 Hands-on polysomnography
Year: 2015
Workstation 2: Data acquisition: what can go wrong? What does it look like when it goes right?
Source: International Congress 2015 – EW27 Hands-on polysomnography
Year: 2015
Workstation 1: Approach to full polysomnography: the basic techniques in terms of setting up and wiring up
Source: International Congress 2015 – EW27 Hands-on polysomnography
Year: 2015
Next-generation sequencing and assessment of tumour mutational burden: are these tools ready for clinical routine use?
Source: International Congress 2019 – Molecular profiling and personalised treatment concepts in advanced non-small cell lung cancer: pertinent clinical dilemmas
Year: 2019
Monitoring at home - telemedicine, how and why?
Source: Annual Congress 2004 - PG21 - Home mechanical ventilation in COPD patients
Year: 2004
Workshop 1: Lung Clearance Index – demonstration of devices utilised by the core facility; best practices and different approaches to communication with pharmaceutical companies
Source: International Congress 2016 – PD5 Establishing core facilities for measuring clinical trial outcomes
Year: 2016
Monitoring of CPAP: poly(somno)graphy and/or in-built software?
Source: ERS Course 2017 - Paediatric noninvasive ventilation
Year: 2017
A patient’s perspective: The use of Oxygen Alert Wrist Bands (OxyBands) in COPD
Source: International Congress 2019 – COPD treatment: cardiovascular, oxygen and vaccination studies
Year: 2019
Using Step Count to Enhance Daily Physical Activity in PH, a pilot-study (STEP in PH).
Source: International Congress 2019 – Pulmonary arterial hypertension: recent advances from the bedside
Year: 2019
Workstation 4: Functional haemodynamic monitoring
Source: International Congress 2015 – EW11 Cardiorespiratory monitoring in critically-ill patients
Year: 2015
Workstation 4: Functional haemodynamic monitoring
Source: International Congress 2015 – EW7 Cardiorespiratory monitoring in critically-ill patients
Year: 2015
Workstation 4: Functional haemodynamic monitoring
Source: International Congress 2015 – EW9 Cardiorespiratory monitoring in critically-ill patients
Year: 2015
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept